Literature DB >> 16385302

Pars plana vitrectomy in ocular injury with intraocular foreign body.

Nihal Demircan1, Merih Soylu, Meltem Yagmur, Handan Akkaya, Altan Atakan Ozcan, Ilter Varinli.   

Abstract

BACKGROUND: We evaluated 70 cases of ocular injuries with intraocular foreign bodies to determine the results of surgical management.
METHODS: The site of penetration was cornea in 58 (82.9%), sclera in 8 (11.4%), and limbus in 4 (5.7%) eyes. The foreign body was in the vitreous in 40 (57.1%) and embedded in the retina in 30 (42.9%) cases. Before pars plana vitrectomy, the most common findings were found to be lens perforation (77.1%), vitreous hemorrhage (45.7%), endophthalmitis (20%), hyphema (4.3%), and retinal detachment (2.9%).
RESULTS: After pars plana vitrectomy, visual acuity improved in 39 (55.7%), did not change in 19 (27.2%), and decreased in 8 (11.4%) cases. We observed secondary glaucoma in 11 (15.7%), retinal detachment in 10 (14.3%), and phthisis bulbi in 3 (4.3%) cases postoperatively.
CONCLUSION: Pars plana vitrectomy is found to be an effective therapeutic approach in removing intraocular foreign bodies, but the preoperative and postoperative complications determine the visual outcome.

Entities:  

Mesh:

Year:  2005        PMID: 16385302     DOI: 10.1097/01.ta.0000196438.48182.ff

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  3 in total

1.  Predictive factors and outcomes of posterior segment intraocular foreign bodies.

Authors:  J Choovuthayakorn; L Hansapinyo; N Ittipunkul; D Patikulsila; P Kunavisarut
Journal:  Eye (Lond)       Date:  2011-09-16       Impact factor: 3.775

2.  25-Gauge Vitrectomy in Open Eye Injury with Retained Foreign Body.

Authors:  G Sborgia; N Recchimurzo; A Niro; L Sborgia; A Sborgia; G Alessio
Journal:  J Ophthalmol       Date:  2017-01-09       Impact factor: 1.909

3.  Surgical outcomes of the removal of posterior segment metallic intraocular foreign bodies.

Authors:  Kai-Ling Peng; Ya-Hsin Kung; Pyn-Sing Hsu; Tsung-Tien Wu
Journal:  BMC Ophthalmol       Date:  2020-07-06       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.